Any current/future new fundraising through debt or equity?

The company is conservative in borrowing and primarily funds CapEx through internal accruals. Planned borrowings are typically around 25-30% of the CapEx requirement, not beyond that. Current term loans and borrowings are for CapEx only, which supports regulatory compliance and capacity enhancement. Debt may initially increase by about 10% in FY’25 due to ongoing projects, but will reduce post project completion and repayment commencement. There is no explicit mention of new equity fundraising in the document. Management states it is too early to predict additional CapEx requirements or relate

Any current/future capex/capital investment/strategic investment?

CapEx spend for FY24 was Rs. 83.2 crores focused on plant and equipment upgradation for European and developed market supply. CapEx planned over the next two years is expected to ease out as most desired capacity and regulatory compliance upgrades are being completed. About 25-30% of future CapEx will be debt-funded, with remaining from internal accruals. Current CapEx aims to create capacity aligned with signed agreements for regulated markets (Europe, Australia, Canada, etc.). CapEx is driven by NIP product capacity build-up and regulatory compliance. Future CapEx will aim to complete capaci

Future growth expectations in sales/revenue/volumes?

The company expects growth in both legacy and new product lines, with easing currency issues in emerging markets aiding recovery. NIP (New Innovative Products) and OTF (Oral Thin Films) segments are expected to grow substantially, potentially contributing 20%-40% of total revenues over the next 2-3 years. NIP revenues were Rs. 24 crore in FY24, with projections to scale up to Rs. 150-200 crore over 3-4 years. Around 14-15 product filings and developments are planned for FY25, with increased capitalized R&D expenditures reflecting growth in pipeline. Export business continues to be sign

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects growth to pick up meaningfully starting FY25, following capacity expansions and new product launches (Anwar Daud, Page 9-10). NIP (New Innovative Products) and OTF segments are projected to grow significantly; NIP plus OTF contribution is anticipated to reach 20%-40% of total business over several years and could contribute Rs. 150-200 crores in revenue in 3-4 years (Page 6-7). EBITDA margin is expected to sustain around 13% in FY25 and FY26 (Page 16). The easing of currency issues and expanding presence in regulated markets (EU, Australia, Canada, etc.) will support revenu

Zim LaboratoriesQ4 FY24

Zim Laboratories Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138.17P/E: 200.4Market Cap: ₹741 Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects growth in both legacy and new product lines, with easing currency issues in emerging markets aiding recovery.
NIP (New Innovative Products) and OTF (Oral Thin Films) segments are expected to grow substantially, potentially contributing 20%-40% of total revenues over the next 2-3 years.
NIP revenues were Rs. 24 crore in FY24, with projections to scale up to Rs. 150-200 crore over 3-4 years.
Around 14-15 product filings and developments are planned for FY25, with increased capitalized R&D expenditures reflecting growth in pipeline.
Export business continues to be significant, contributing 78% in FY24 with steady domestic market growth seen as sustainable.
Capacity utilization for NIP is currently low (~10-15%), with scope to increase up to 40%, supporting higher future volumes.
Management is confident that from FY25 onwards, substantial revenue and margin growth will materialize due to new regulated market focus and product launches.

Margin guidance

Category 3

The company expects growth to pick up meaningfully starting FY25, following capacity expansions and new product launches (Anwar Daud, Page 9-10).
NIP (New Innovative Products) and OTF segments are projected to grow significantly; NIP plus OTF contribution is anticipated to reach 20%-40% of total business over several years and could contribute Rs. 150-200 crores in revenue in 3-4 years (Page 6-7).
EBITDA margin is expected to sustain around 13% in FY25 and FY26 (Page 16).
The easing of currency issues and expanding presence in regulated markets (EU, Australia, Canada, etc.) will support revenue and profit growth (Page 18, Page 6).
The company aims for better asset turnover, targeting about 2.5 times asset terms with increased capacity utilization from NIP products (Page 21).
Conservative about giving explicit future revenue or EPS guidance but optimistic about growth momentum from FY25 onward (Page 16, 9).

See what Zim Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company is conservative in borrowing and primarily funds CapEx through internal accruals.
Planned borrowings are typically around 25-30% of the CapEx requirement, not beyond that.
Current term loans and borrowings are for CapEx only, which supports regulatory compliance and capacity enhancement.
Debt may initially increase by about 10% in FY’25 due to ongoing projects, but will reduce post project completion and repayment commencement.
There is no explicit mention of new equity fundraising in the document.
Management states it is too early to predict additional CapEx requirements or related borrowings beyond the current plan.
Overall, future debt is expected to remain controlled and primarily linked to CapEx, with no clear indication of equity fundraising at this time.

Order book

The transcript provided from the ZIM Laboratories Limited earnings call does not explicitly mention details regarding the current or expected order book or pending orders. However, from the management discussion, some relevant points include: - The company is completing several projects and plans around 14-15 filings and product developments in FY25, indicating a growing project pipeline. - They have signed agreements with partners for their NIP products, which signals active business engagements. - The company expects growth in regulated markets like Europe, Australia, Canada, etc., with multiple filings and upcoming marketing authorizations. - The inventory was built up for marketing planning and most has been delivered, stabilizing inventory levels. - Debt may initially increase due to ongoing projects but will reduce post project completion and repayments. No exact order book or pending order value was shared explicitly in the call transcript.

See what Zim Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes

CapEx spend for FY24 was Rs. 83.2 crores focused on plant and equipment upgradation for European and developed market supply.
CapEx planned over the next two years is expected to ease out as most desired capacity and regulatory compliance upgrades are being completed.
About 25-30% of future CapEx will be debt-funded, with remaining from internal accruals.
Current CapEx aims to create capacity aligned with signed agreements for regulated markets (Europe, Australia, Canada, etc.).
CapEx is driven by NIP product capacity build-up and regulatory compliance.
Future CapEx will aim to complete capacity for servicing agreements and market share targets.
Additional CapEx may be considered later, but not finalized at this time.
Warehouse investment of ~Rs. 22 crores has been made.
Capitalized R&D costs are expected to increase in FY25 due to higher filings and registration expenses, especially for Europe.

Track Zim Laboratories — get its next earnings analysis in your feed

How does Zim Laboratories rank vs peers in ?

Pro feature

ThisZim Laboratories

Rev 3Mar 3

See where Zim Laboratories sits in See which companies these are, and every other name in the sector.Open rankings

What Zim Laboratories's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Zim Laboratories Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Zim Laboratories's management said in earlier quarters